A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

NCT05268003 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped \< 75% participation

Conditions

Acute Lymphoblastic Leukemia
Leukemia

Interventions

DRUG: Ponatinib
DRUG: Venetoclax
DRUG: Mini-hyper CVD

Sponsor

M.D. Anderson Cancer Center